VEGF in idiopathic ILD

Simler et al raise an interesting possibility of the prognostic value of plasma VEGF in interstitial lung disease.1 Meyer et al2 in a previous study did not find any difference in serum VEGF165 levels in patients with diffuse parenchymal lung disease. It would have been interesting to know the bronchoalveolar lavage (BAL) fluid levels of VEGF in these patients as Meyer et al2 and Koyama et al3 have shown reduced BAL fluid VEGF levels in interstitial lung disease. This might simply reflect damage to the alveolar epithelium (a known major source) in this disease or, indeed, VEGF may have an important role in the pathogenesis of interstitial disease. Interestingly, VEGF receptor blockade has been shown to lead to an induction of angiogenesis in alternative areas of the lung.4

In addition, it is interesting to speculate on the cellular source of the increased plasma levels of VEGF in the more fibrotic patients. Could this alveolar-capillary membrane damage with leakage of intra-alveolar VEGF which is known to be compartmentalised and hence lower BAL fluid levels as described in the previous studies?5 Or does it represent an inflammatory mediator induced by the increased permeability of the alveolar wall? The cellular source of systemic VEGF correlating with an inflammatory response that is here associated with a poorer outcome? Or is there some other mechanism?

Finally, Koyama et al3 have shown that smokers also have reduced BAL fluid levels of VEGF and is consistent with their own data and, this range is quoted by the kit manufacturers for 15 min. This will


Authors’ reply

Dr Medford laudably highlights the interesting findings of other authors regarding levels of vascular endothelial growth factor (VEGF) in idiopathic interstitial pneumonia (IIP). Indeed, our data reflect the findings of Meyer et al who studied 11 patients with IIP. We extend their observations in a larger cohort of patients (n=49) and specifically relate plasma VEGF levels to disease progression and extent of fibrosis on HRCT scanning.6 Indeed, HRCT scanning is perhaps the most reliable surrogate for the extent of disease.3 Like Meyer et al, we observed reduced VEGF levels in bronchoalveolar lavage (BAL) fluid levels of VEGF in patients with IIP (91 pg/ml) compared with controls (204 pg/ml). The reduction in the BAL fluid level of VEGF may reflect the absence of angiogenesis in that specific part of the lung, with the plasma VEGF level identifying a secondary phenomenon of compensatory angiogenesis in alternative areas of the lung. Alternatively, VEGF levels appear to be higher in epithelial surface fluid than in the serum, suggesting vectorial intraluminal secretion and the existence of a concentration gradient from air spaces to intravascular spaces.7

Thickett et al8 are correct in their quotation of the normal range for VEGF in plasma (36–76 pg/ml) as measured by the R&D Systems Quantikine ELISA kit. They point out that this range is quoted by the kit manufacturer and is consistent with their own data and, indeed, with other published studies.3 We did not use the Quantikine kit in this study but stated clearly that: “The ELISA capture and detection antibodies for assaying IL-8 and VEGF were selected paired reagents optimised for ELISA use by R&D Systems”. R&D currently sell these paired reagents under the name “DuoSet”.

Different ELISA formats for VEGF quantitation using recombinant VEGF165 as standard are available. Capture reagent: (1) rabbit polyclonal antiVEGF (in house); (2) soluble flt-1 (Sflt-1); (3) Quantikine kit, mouse anti-VEGF; (4) Duoset, mouse anti-VEGF. Detection reagent: (1) mouse anti-VEGF (Genetech 4.6.1); (2) rabbit anti-VEGF; (3) mouse anti-VEGF; (4) mouse anti-VEGF. Not surprisingly, each assay reports a different normal range. In our experience the Quantikine kit measures low (with up to a third of samples having undetectable levels) and the DuoSet combination measures high, as we reported in the article (468 pg/ml). The other assays report intermediate values.

A number of possibilities exist as to why these assays read differently. It is unlikely to be due to platelet release as suggested. The greatest difference in VEGF levels that is detected between paired serum (complete platelet release of VEGF) and standard plasma samples (low platelet VEGF release) is at most only three to four fold. Similarly, the difference in VEGF between paired platelet poor and platelet rich plasma samples is of the same order of magnitude. To demonstrate this one has to spin plasma samples at 2700g for 15 min to prepare platelet poor samples. In our experience it is important to use plasma rather than serum samples to quantitate VEGF levels as different antibodies could treat each study sample similarly in terms of centrifugation—whether it be 300g for 12 min, 1000g for 15 min, or 2700g for 15 min. This will minimise variation in the study samples due to the “platelet release effect”.

There are possible explanations for the VEGF immunoassays reading differently in plasma. It may be a combination of at least two effects—the nature of the epitope detected and the presence of other competing ligands in the sample. Different antibodies raised to VEGF will react variably with available epitopes on the ligand. This can be quite striking with monoclonal antibodies to different epitopes of a ligand when they are used as ELISA capture reagents. Antibody A reacts with an epitope on VEGF that is close to or part of the flt-1 receptor binding site and the other antibody B reacts with an epitope well removed from this site, with an identical absolute amount of VEGF in the plasma sample, antibody A would read low or negative and antibody B would read high in relation to the amount of sflt-1 present in the plasma sample. We have in fact shown that the capture antibody used in the Quantikine VEGF ELISA is, indeed, sensitive to the presence of sflt-1.

In addition to this potential variation in the level of free VEGF and VEGF-sflt-1 complexes in plasma samples, a further confounding factor is the amount of placenta growth factor (PLGF). VEGF is a natural homodimer but it does form heterodimers with PLGF and we have detected such complexes.6 Antibodies detecting epitopes that are variably modified by the binding of PLGF to VEGF will read low or high depending on the PLGF concentration. This focuses on the nature of the R&D Systems monoclonal antibodies to VEGF—one in the Quantikine kit and the other in the DuoSet. Following the recognition of a difference in performance of these two assays, we contacted R&D Systems for information concerning the nature of these antibodies. We were interested to know if the same antibody or different antibodies were used and what information was available on their specificity. The response from R&D Systems was that the capture antibodies were different, so the scenario outlined above is a possible explanation.

It may well be that the difficulties in interpreting absolute levels of VEGF in complex media such as plasma. To do this rigorously one ought to quantitate not only free VEGF but also VEGF complexes with sflt-1, sKDR, and PLGF to understand how one interprets measurements of one antibody against another, and currently this is not possible. It would be simplistic to think that the Quantikine kit values are the “true” VEGF values and the DuoSet assay values artefactual. It might simply reflect the different antibodies used. The Quantikine values are free VEGF and the DuoSet values total VEGF (free VEGF plus VEGF complexes).

If you have a burning desire to respond to a paper published in Thorax, why not make use of our “rapid response” option? Log on to our website (www.thoraxjnl.com), find the paper that interests you, and send your response via email by clicking on the “eLetters” option in the box at the top right-hand corner.

Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eletters” on our homepage.

The editors will decide as to whether to accept it in a future paper issue.

References


A R L Medford

Lung Research Group, Division of Medicine, Southmead Hospital, Bristol BS8 3LP, UK; andrew.medford@bristol.ac.uk

PostScript

LETTERS TO THE EDITOR

353
The important observation in our study is not the absolute VEGF plasma values but the relative differences in VEGF levels between patients and control samples over time, where the sampling issues have been fully appreciated and rigorously controlled to allow clinical interpretation of the results. We have emphasised the prognostic value of plasma VEGF in idiopathic pulmonary fibrosis and have shown a significant positive relationship between the HRCT fibrosis score and the plasma concentration of VEGF. A comparison with acute respiratory distress syndrome (ARDS) is not useful and perpetuates the concept that ARDS equates with chronic idiopathic pulmonary fibrosis, which is not the case.

In relation to the point about quantitating local VEGF concentrations in the lung where the influence of epithelial sflt-1 might be greater, it is to be expected that different assays could lead to a variation in reported VEGF levels for the reasons already discussed.

In conclusion, we have complete confidence in the validity and reproducibility of the VEGF data presented. In a situation of excess VEGF production which could potentially be driving an angiogenic fibrotic pathology in the lung, we suggest it is entirely appropriate to contemplate antagonising excess VEGF in order to control the disease pathophysiology. Overdosing on VEGF antagonist is clearly counterproductive and, as stated, could lead to the apoptosis of both epithelial and endothelial cells. Clearly, it is a case of restoring homeostasis.

J Salom
Department of Respiratory Medicine, Mater Misericordiae University Hospital, University College Dublin, Dublin 7, Ireland

P E Brchellcy
Renal Research Laboratory, Manchester Royal Infirmary, Manchester M3 3LW, UK

N R Simler
Royal Brompton Hospital, London, UK

J J Egan
Department of Respiratory Medicine, Mater Misericordiae University Hospital and St Vincents University Hospital, University College Dublin, Dublin 7, Ireland

Correspondence to: Dr J J Egan, Advanced Lung Disease and Lung Transplant Program, Dublin Molecular Medicine Center, The Mater Misericordiae University Hospital and St Vincent’s University Hospital, University College Dublin, Dublin 7, Ireland; jegan@mater.ie

References

CARD 15 gene mutations in sarcoidosis

In the last few years substantial progress has been made in unravelling the genetic basis of susceptibility to Crohn’s disease. Three CARD 15 (previously called NOB1) gene variants, resulting in proteins with modified carboxy termini, have been implicated.

43% of patients with a first relapse of Crohn’s disease carry at least one of these CARD 15 mutations (compared with 1% of healthy controls). Mutations in CARD 15 have also been identified in affected members of families with Blau syndrome. This is a rare autosomal dominant disorder, sometimes referred to as familial sarcoidosis, characterised by granuloma formation in joints, skin, and uvea. Card 15 is a microbial sensing protein involved in innate immunity. It recognises conserved structural components of microorganisms (bacterial muramyl dipeptide, MDP and peptidoglycan, PGN) and is part of the danger signal pattern recognition network which forms the front line of protective immunity. Mutations associated with Crohn’s disease render the molecule insensitive to MDP and interfere with the downstream activation of NF-kB. One potential result of this may be the persistence of an inflammatory state and resulting engagement of other arms of the adaptive immune system and formation of granulomas. Expression of CARD 15 in monocytes (precursors of macrophages and granulomas) further supports its role in granuloma formation. We hypothesised that mutations in CARD 15 may be a unifying defect in the multisystemic granulomatous diseases of Crohn’s disease, sarcoidosis, and Blau syndrome.

To investigate this, we sampled a cohort of 29 patients with sarcoidosis from the Oxford Centre for Respiratory Medicine. All had a typical clinical picture of sarcoidosis and either histologically proven disease or characteristic Lofgren’s syndrome (defined as an acute onset of disease with erythema nodosum, joint pains, and bilateral hilar lymphadenopathy). The diagnosis of sarcoidosis was also supported by the characteristic appearance of the lungs on a high resolution computed tomographic (CT) scan in all patients. The definition and diagnosis of sarcoidosis adheres to the statement on sarcoidosis adopted by the scientific committees of WASOG/ATS/ERS. The patients were first diagnosed between the ages of 25 and 40 years and had been followed up for at least 1 year before recruitment. All were white and one third presented with Lofgren’s syndrome. Written informed consent was obtained for genetic analysis and the study was approved by the local ethics committee.

The entire coding region of CARD 15 (11 exons and flanking intronic sequences) was screened for the presence of mutations. In brief, the CARD 15 gene was amplified from the genomic DNA samples by polymerase chain reaction (PCR) using primers as previously described and sequenced on an ABI 377 automated sequencer using a Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer Applied Biosystems, CA, USA). Sequence data were then aligned using the Sequence Navigator analysis software Version 1.0.1 (Perkin Elmer Applied Biosystems) and compared with the known CARD 15 sequence (EMBL accession number A303140). 435 sequence analyses were performed in the 29 patients. We were therefore able to detect new alleles putatively associated with the sarcoidosis phenotype with frequencies as low as 2%. The three mutations associated with Crohn’s disease were specifically examined. The R702W mutation was observed in one patient with sarcoidosis while the G908R and the 1007F mutations were not found. These results were not different from those reported previously in control populations where the mutations R702W, G908R and 1007F were present in 4%, 1%, and 2% of 103 European healthy controls. Further, they do not differ from data derived from healthy controls recruited in the UK.

The codons 334 and 469 reported to be involved in the Blau syndrome were also carefully scrutinised but we did not detect any genetic variation in our sarcoidosis patients. No additional mutations were seen within the rest of the coding region of the gene, suggesting that there were no specific alternative CARD 15 mutations associated with sarcoidosis. Furthermore, colleagues recently found no correlation between specific CARD 15 polymorphic alleles and patients with sarcoidosis from France with more than one member afflicted by the disease. This study provides evidence that CARD 15 is not associated with non-familial sarcoidosis (in patients with a white ethnic background) and that there are no mutations in any part of the coding region of the CARD 15 gene in the French sarcoidosis population.

There is little doubt that there is a genetic predisposition in sarcoidosis, as indicated by the presence of familial clustering, ethnic susceptibility, and recent evidence of an association with HLA-DRB1. Further, for this susceptibility gene(s) has recurrently pointed to a locus near the HLA DR region on chromosome 6. This and the exclusion of the NOB2 locus has focused attention on abnormalities in antigen presentation and cytokine/chemokine receptors as a potential basis for the aetiology of sarcoidosis.

L P Ho, A J McMichael
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK

L P Ho, R J O Davies
Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford OX3 7LJ, UK

K Gabor
Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK

J-P Hugot, F Merlin
Fondation Jean Dausset/CEPH, Paris, France

J-P Hugot
INSERM U458, Hopital Robert Debré, AP-HP, Paris, France

www.thoraxjnl.com
This study received funding from the MRC (UK), Oxfordshire Health Research Committee, the Foundation for Research and Education in Medicine, and the Oxford Centre for the Study of Cardiovascular Disease. Dr. P.T. Ho is a recipient of an MRC Fellowship.

References


Infected pulmonary sequestration caused by Mycobacterium kansasii

Mycobacterium kansasii is the second most commonly reported nontuberculous mycobacterium associated with lung disease in the United States. Diseases are almost always cavitary, involving the upper lobes with fibrosis and infiltrations. Underlying pulmonary diseases associated with M kansasii infection include pneumoconiosis, chronic obstructive lung disease, AIDS and malignancy. To our knowledge, M kansasii has never been reported in the English literature in the aetiology of infected pulmonary sequestration. We report a case of intralobar sequestration complicated by infection with M kansasii.

A 33 year old man was previously healthy. An abnormal finding on the chest radiograph had been noted at a routine health check 1.5 years earlier. He had no history of medical illness and no risk factors for HIV infection. No symptoms attributed to his respiratory system, such as cough, haemoptysis or dyspnoea, were noted. Constitutional symptoms including malaise, fever, night sweats, anorexia, or weight loss were lacking. Physical examination revealed systolic bruit at the left basal lung. There was neither cyanosis nor digital clubbing. Oxygen saturation by pulse oximetry was 99% while breathing room air. Blood laboratory studies disclosed a white blood cell (WBC) count of 7.4 x 10^3 (neutrophils 60.7%, lymphocytes 13.6%), and the level of carcinoembryonic antigen (CEA) was 1 ng/ml (reference value ≤ 3 ng/ml). Sputum acid-fast stain and mycobacterial cultures were all negative. Bronchoscopic examination showed no endobronchial abnormality. A chest radiograph taken at admission and a computed tomographic scan showed a patchy consolidation over the left basal lung. Magnetic resonance imaging (MRI) and angiography of the chest showed that an aberrant bronchial artery had arisen from the left side of the thoracic aorta and crossed the territory of the consolidation patch, but the venous drainage could not be visualised clearly (fig 1).

The patient underwent lobectomy of the left lower lobe by video-assisted thoracoscopic surgery (VATS). A 14 x 10 cm area of consolidation over the left lower lobe was noted and cystic formation and profuse sputum were found within the lesion. The three feeding arteries from the aorta at the level of the 10th thoracic spine were seen. Microscopically, the parenchyma revealed bronchiolitis and microabscess formation. Granulomatous inflammation was also present, but no organisms were identified by fast acid and Grocott’s methenamine silver (GMS) stains (fig 2). The biopsy tissue was ground and inoculated onto Lowenstein-Jensen slant (BBL Microbiology Systems, Cockeysville, MD, USA) and cultured at 35°C in a CO2 incubator. After 19 days of incubation the culture yielded a photochromogen which was later identified as M kansasii using conventional biochemical methods. The patient had an uneventful postoperative course and was discharged soon after operation. No anti-mycobacterial regimen was administered after the diagnosis was made and his clinical status remained uneventful at the 3 month follow up.

Pulmonary sequestration is a congenital malformation characterised by the presence of lung tissue with abnormal or absent communication with the bronchial tree and arterial blood supply from the systemic circulation. Despite the high frequency of infection, few data are available regarding specific infecting organisms. Acute infections due to bacteria such as Staphylococcus and Pseudomonas have been reported, and some chronic infections due to Aspergillus and Nocardia have also been described. Infected pulmonary sequestration due to mycobacteria including M tuberculosis and M avium-intracellularare have been reported only rarely. In our case, M kansasii was the first organism thought to be responsible for the infection of pulmonary sequestration in the absence of other pulmonary or extrapulmonary involvement. It is assumed that the organism reaches the sequestration through Kohn’s pore without causing evident disease in the normal lung parenchyma.

The combination of isoniazid, rifampin, and ethambutol was recommended for treatment of M kansasii pulmonary disease. However, surgical removal should be advocated in both asymptomatic and symptomatic cases of pulmonary sequestration and the benefit of a period of preoperative antimicrobial treatment in infected pulmonary sequestration has been debated. Our patient simply underwent a surgical resection and did not receive any anti-mycobacterial agents.

We have reported the unique occurrence of pulmonary sequestration with M kansasii infection. Surgical resection allows establishment of the exact diagnosis and immediate removal of the infectious focus, thus preventing complications related to the infection or to the malformation itself.

S H Lin
Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei County, Taiwan

L N Lee, Y L Chang, Y C Lee, L W Ding, P R Hsueh
Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, No 7, Chung-Shan South Road, 100 Taipei, Taiwan; hspon@na.mc.ntu.edu.tw

References


www.thoraxjnl.com
Infected pulmonary sequestration caused by *Mycobacterium kansasii*

S H Lin, L N Lee, Y L Chang, Y C Lee, L W Ding and P R Hsueh

*Thorax* 2005 60: 355
doi: 10.1136/thx.2004.037705

Updated information and services can be found at:
http://thorax.bmj.com/content/60/4/355

These include:

**References**
This article cites 6 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/60/4/355#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/